Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3268331 | Endocrinology and Metabolism Clinics of North America | 2008 | 24 Pages |
Abstract
Radioactive iodine remnant ablation (RRA) is used to destroy residual normal thyroid tissue after complete gross surgical resection of papillary or follicular thyroid cancer. The article updates a prior systematic review of the literature to determine whether RRA decreases the risk of thyroid cancer-related death or recurrence at 10 years after initial surgery, including data from 28 studies. No long-term randomized trials were identified, so the review is limited to observational studies. The incremental benefit of RRA in low risk patients with well-differentiated thyroid cancer after total or near-total thyroidectomy who are receiving thyroid hormone suppressive therapy remains unclear.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Anna M. MD, PhD, FRCPC, James D. MBBS, FRCP, FRCR, FRCP(C), Richard W. MD, FRCP(C), Lehana PhD, Lorne MD, FRCSC, Amiram PhD, Sharon MD, MSc, FRCPC, David P. MD, FRCSC,